The suit was filed in the Delhi Court by the UK-based biopharmaceutical company AstraZeneca against Dr Reddy’s Laboratories Ltd to prevent them from launching the generic version of the drug Brilinta. One of the key patents of AstraZeneca had expired in India providing opportunities of evergreening by local drug manufacturers.
Vide Order dated 18 July 2018 passed by Justice Jayant Nath of the Delhi High Court, an interim order was passed “restraining the defendant from marketing, selling, distributing, advertising or offering for sale any product which is directly or indirectly dealing with or infringes the subject matter patent being IN 209907, IN 247984 and IN 272674.”
The order holds importance as despite the contentions of the defendant, the Court was pleased to find that the plaintiff has a prima facie case and granted an injunction under Order XXXIX Rules 1 and 2, CPC.
The Anand and Anand team representing the petitioner were Pravin Anand, Nishchal Anand and Sanchith Shivakumar.